Market Cap | 3.09B | P/E | - | EPS this Y | 9.60% | Ern Qtrly Grth | - |
Income | -31.75M | Forward P/E | 18.30 | EPS next Y | 9.80% | 50D Avg Chg | 14.00% |
Sales | 1.19B | PEG | -4.46 | EPS past 5Y | 0.02% | 200D Avg Chg | 15.00% |
Dividend | N/A | Price/Book | 2.49 | EPS next 5Y | -4.60% | 52W High Chg | -14.00% |
Recommedations | 2.00 | Quick Ratio | 1.58 | Shares Outstanding | 54.15M | 52W Low Chg | 43.00% |
Insider Own | 0.50% | ROA | 2.31% | Shares Float | 51.09M | Beta | 0.94 |
Inst Own | 105.63% | ROE | -2.59% | Shares Shorted/Prior | 3.09M/3.49M | Price | 57.46 |
Gross Margin | 67.93% | Profit Margin | -2.68% | Avg. Volume | 407,064 | Target Price | 71.00 |
Oper. Margin | 8.55% | Earnings Date | Jul 24 | Volume | 231,748 | Change | -1.88% |
LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products. The Neuromodulation segment designs, develops, markets, and sells VNS Therapy System, an implantable pulse generator and connective lead that stimulates the vagus nerve; difficult-to-treat depression and drug-resistant epilepsy devices. The Advanced Circulatory Support segment develops, produces, and sells temporary life support products. It serves perfusionists, neurologists, neurosurgeons, and other physicians, as well as hospitals, other medical institutions, and healthcare providers. The company sells its products through direct sales representatives and independent distributors. LivaNova PLC was incorporated in 2015 and is headquartered in London, the United Kingdom.
Mizuho | Buy | May 2, 24 |
Baird | Neutral | May 2, 24 |
Needham | Buy | May 1, 24 |
Mizuho | Buy | Mar 27, 24 |
Needham | Buy | Mar 20, 24 |
Barclays | Equal-Weight | Feb 27, 24 |
Barclays | Equal-Weight | Feb 26, 24 |
Baird | Neutral | Feb 22, 24 |
Mizuho | Buy | Feb 22, 24 |
Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
---|---|---|---|---|---|---|---|---|
Moore Daniel Jeffrey | Director Director | Apr 01 | Sell | 83.416 | 1,000 | 83,416 | 24,630 | 04/05/22 |
Shvartsburg Alex | CFO CFO | Mar 30 | Option | 20.38 | 2,352 | 47,934 | 5,425 | 04/01/22 |
McDonald Damien | CEO CEO | Mar 29 | Option | 0 | 16,940 | 88,376 | 03/31/22 | |
McDonald Damien | CEO CEO | Mar 29 | Sell | 81.5 | 2,784 | 226,896 | 76,993 | 03/31/22 |
Moore Daniel Jeffrey | Director Director | Mar 02 | Sell | 80 | 1,000 | 80,000 | 25,630 | 03/03/22 |
Moore Daniel Jeffrey | Director Director | Feb 25 | Sell | 80 | 1,000 | 80,000 | 26,630 | 03/01/22 |
Novak Alfred J | Director Director | Nov 10 | Sell | 89.97 | 2,981 | 268,201 | 11,368 | 11/12/21 |
Dolci Marco | SVP Global Operation.. SVP Global Operations, R&D | May 20 | Option | 43.57 | 3,926 | 171,056 | 3,926 | 05/20/21 |
Dolci Marco | SVP Global Operation.. SVP Global Operations, R&D | May 20 | Sell | 83.05 | 8,278 | 687,488 | 05/20/21 |